Results 171 to 180 of about 29,074 (242)

Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer. [PDF]

Front Immunol
Frontiers Production Office.
europepmc   +1 more source

Bispecific Antibody 4G7xH22 [PDF]

, 2020
openaire   +1 more source

Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases

Advanced Science, Volume 13, Issue 13, 3 March 2026.
Genetic fusion of a CD38 enzymatic domain to antibody scaffolds allows site‐specific conjugation of small‐molecule ligands. Using this approach, a PSMA ligand DUPA is conjugated with an anti‐human CD3 Fab antibody. The resulting bispecific anti‐CD3‐DUPA conjugate facilitates recruitment and activation of cytotoxic T cells against PSMA‐expressing ...
Sunny H. Kim, Arshad J. Ansari, Lei Zhang, Guoyun Kao, Thuc Oanh Hoang, Zeyu Zhang, Srinivasarao Singireddi, Benjamin B. Katz, Yong Zhang   +8 more
wiley   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility. [PDF]

Cancer Med
Abou DS, Thalib HI, Akil F, Sabbagh SZ, Abou HS, Pereira M, Hassan FE.   +6 more
europepmc   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Nanobody-based IgG simultaneously inhibit the allergenic and enzymatic activity of the dominant honeybee venom allergen. [PDF]

Nat Commun
Aagaard JB, Gandini R, Ballegaard AR, Jensen BK, Dorn B, Larsen AVB, Lenstrup A, Sønderholm M, Miehe M, Pfützner W, Jakob T, Andersen GR, Möbs C, Spillner E.   +13 more
europepmc   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, Volume 13, Issue 14, 9 March 2026.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer. [PDF]

Cancer Immunol Immunother
Ye Y, Liu T, Cheng C, Wang H, Shen J, He X, Xu S.   +6 more
europepmc   +1 more source

Extramedullary Disease—Achilles Heel in Myeloma?

American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar, Joshua Richter, Saad Z. Usmani, Yael C. Cohen, Jing Christine Ye, María‐Victoria Mateos, Vania Hungria, Elena Zamagni   +7 more
wiley   +1 more source